Restricted accessResearch articleFirst published online 2018-12
Prevalence of CTX-M-Type Extended-Spectrum β-Lactamase-Producing Escherichia coli B2-O25-ST131 H30 R Among Residents in Nonacute Care Facilities in Japan
We investigated the prevalence and characteristics of extended-spectrum β-lactamase (ESBL)-producing Escherichia coli among 258 residents of long-term care facilities (LTCFs) in Japan. Out of 258 fecal samples collected from nine LTCFs between November 2015 and March 2017, we recovered 59 ESBL-producing E. coli isolates. All isolates carried blaCTX-M genes, mainly blaCTX-M-27 (42.4%), blaCTX-M-14 (23.7%), and blaCTX-M-15 (18.6%). The isolates showed 7 serotypes (STs), including ST131 (n = 49, 83.1%) and ST38 (n = 4, 6.8%), and 47 (79.7%) out of 49 isolates belonging to ST131 were identified as H30R. The 59 ESBL producers were divided into four groups, B2 (86.4%), D (8.5%), A (3.4%), and C (1.7%); 44 (74.6%) were epidemic clone B2-O25-ST131 H30R, of which 21, 11, and 6 harbored blaCTX-M-27, blaCTX-M-15, and blaCTX-M-14, respectively. Most plasmids were of IncF replicon types (n = 33), and 22 blaCTX-M-27-carrying plasmids showed multiple replicon types, including IncFII, FIA, and FIB. The ESBL producers were susceptible to imipenem, amikacin, and fosfomycin, but resistant to ceftazidime (49.2%), and ciprofloxacin (88.1%); in particular, the isolates harboring the blaCTX-M-15 gene showed significantly high resistance rate to ceftazidime (p < 0.01). Our findings indicate that a considerable proportion of the examined LTCF residents carried ESBL-producing E. coli isolates in feces and had high prevalence of epidemic clone B2-O25-ST131. Furthermore, continuous investigations would be very necessary to monitor actual carriage states of ESBL-producers among the LTCF residents from the viewpoint of both public health and healthcare viewpoints.
Get full access to this article
View all access options for this article.
References
1.
SpellbergB., BartlettJ.G., and GilbertD.N.. 2013. The future of antibiotics and resistance. N. Engl. J. Med., 368:299–302.
2.
PeiranoG., and PitoutJ.D.. 2010. Molecular epidemiology of Escherichia coli producing CTX-M β-lactamases: the worldwide emergence of clone ST131 O25:H4. Int. J. Antimicrob. Agents., 35:316–321.
3.
Fernández-ReyesM., VicenteD., GomarizM., EsnalO., LandaJ., OñateE., and Pérez-TralleroE.. 2014. High rate of fecal carriage of extended-spectrum-β-lactamase-producing Escherichia coli in healthy children in Gipuzkoa, northern Spain. Antimicrob. Agents Chemother., 58:1822–1824.
4.
RodriguesC., MachadoE., FernandesS., PeixeL., and NovaisÃ.. 2016. An update on faecal carriage of ESBL-producing Enterobacteriaceae by Portuguese healthy humans: detection of the H30 subclone of B2-ST131 Escherichia coli producing CTX-M-27. J. Antimicrob. Chemother. 71:1120–1122.
5.
LiB., SunJ.Y., LiuQ.Z., HanL.Z., HuangX.H., and NiY.X.. 2011. High prevalence of CTX-M β-lactamases in faecal Escherichia coli strains from healthy humans in Fuzhou, China. Scand. J. Infect. Dis., 43:170–174.
6.
NakaneK., KawamuraK., GotoK., and ArakawaY.. 2016. Long-term colonization by blaCTX-M-producing Escherichia coli in healthy Japanese people engaged in food handing. Appl. Environ. Microbiol., 82:1818–1827.
7.
DhanjiH., DoumithM., RooneyP.J., O'LearyM.C., LoughreyA.C., HopeR., WoodfordN., and LivermoreD.M.. 2011. Molecular epidemiology of fluoroquinolone-resistant ST131 Escherichia coli producing CTX-M extended-spectrum β-lactamases in nursing homes in Belfast, UK. J. Antimicrob. Chemother., 66:297–303.
8.
ArvandM., MoserV., and PfeiferY.. 2013. Prevalence of extended-spectrum β-lactamase-producing Escherichia coli and spread of the epidemic clonal lineage ST131 in nursing homes in Hesse, Germany. J. Antimicrob. Chemother., 68:2686–2688.
9.
ZhaoS.Y., ZhangJ., ZhangY.L., WangY.C., XiaoS.Z., GuF.F., GuoX.K., NiY.X., and HanL.Z.. 2016. Epidemiology and risk factors for faecal extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) carriage derived from residents of seven nursing homes in western Shanghai, China. Epidemiol. Infect., 144:695–702.
10.
FlokasM.E., AlevizakosM., ShehadehF., AndreatosN., and MylonakisE.. 2017. Extended-spectrum β-lactamase-producing Enterobacteriaceae colonization in long-term care facilities: a systematic review and meta-analysis. Int. J. Antimicrob. Agents., 50:649–656.
PäivärintaM., PohjolaL., Fredriksson-AhomaaM., and HeikinheimoA.. 2016. Low occurrence of extended-spectrum β-lactamase-producing Escherichia coli in Finnish food-producing animals. Zoonoses Public Health., 63:624–631.
15.
ShibataN., KurokawaH., DoiY., YagiT., YamaneK., WachinoJ., SuzukiS., KimuraK., IshikawaS., KatoH., OzawaY., ShibayamaK., KaiK., KondaT., and ArakawaY.. 2006. PCR classification of CTX-M-type β-lactamase genes identified in clinically isolated gram-negative bacilli in Japan. Antimicrob. Agents Chemother., 50:791–795.
16.
KawamuraK., SugaharaT., MatsuoN., HayashiK., NorizukiC., TamaiK., KondoT., and ArakawaY.. 2017. Spread of CTX-type extended-spectrum β-lactamase-producing Escherichia coli isolates of epidemic clone B2-O25-ST131 among dogs and cats in Japan. Microb. Drug Resist., 23:1059–1066.
17.
SuzukiS., ShibataN., YamaneK., WachinoJ., ItoK., and ArakawaY.. 2009. Change in the prevalence of extended-spectrum-β-lactamase-producing Escherichia coli in Japan by clonal spread. J. Antimicrob. Chemother., 63:72–79.
18.
YagiT., KurokawaH., ShibataN., ShibayamaK., and ArakawaY.. 2000. A preliminary survey of extended-spectrum β-lactamases (ESBLs) in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Japan. FEMS Microbiol. Lett., 184:53–56.
19.
Pérez-PérezF.J., and HansonN.D.. 2002. Detection of plasmid-mediated AmpC β-lactamase genes in clinical isolates by using multiplex PCR. J. Clin. Microbiol., 40:2153–2162.
20.
RodríguezI., ThomasK., van EssenA., SchinkA.K., DayM., ChattawayM., WuG., MeviusD., HelmuthR., GuerraB., and consortiumSAFEFOODERA-ESBL. 2014. Chromosomal isolation of blaCTX-M genes in clinical isolates of Escherichia coli from Germany, The Netherlands and the UK. Int. J. Antimicrob. Agents., 43:553–557.
21.
CarattoliA., BertiniA., VillaL., FalboV., HopkinsK.L., and ThrelfallE.J.. 2005. Identification of plasmids by PCR-based replicon typing. J. Microbiol. Methods., 63:219–228.
22.
ClermontO., ChristensonJ.K., DenamurE., and GordonD.M.. 2013. The Clermont Escherichia coli phylo-typing method revisited: improvement of specificity and detection of new phylo-groups. Environ. Microbiol. Rep., 5:58–65.
23.
ColpanA., JohnstonB., PorterS., ClabotsC., AnwayR., ThaoL., KuskowskiM.A., TchesnokovaV., SokurenkoE.V., and JohnsonJ.R.; on behalf of the VICTORY (Veterans Influence of Clonal Types on Resistance: Year 2011) Investigators. 2013. Escherichia coli sequence type 131 (ST131) subclone H30 as an emergent multidrug-resistant pathogen among US veterans. Clin. Infect. Dis., 57:1256–1265.
24.
PriceL.B., JohnsonJ.R., AzizM., ClabotsC., JohnstonB., TchesnokovaV., NordstromL., BillingM., ChattopadhyayS., SteggerM., AndersenP.S., PearsonT., RiddellK., RogersP., ScholesD., KahlB., KeimP., and SokurenkoE.V.. 2013. The epidemic of extended-spectrum-β-lactamase-producing Escherichia coli ST131 is driven by a single highly pathogenic subclone, H30-Rx. MBio., 4: e00377-13.
25.
BanerjeeR., RobicsekA., KuskowskiM.A., PorterS., JohnstonB.D., SokurenkoE., TchesnokovaV., PriceL.B., and JohnsonJ.R.. 2013. Molecular epidemiology of Escherichia coli sequence type 131 and its H30 and H30-Rx subclones among extended-spectrum-β-lactamase-positive and -negative E. coli clinical isolates from Chicago region, 2007 to 2010. Antimicrob. Agents Chemother., 57:6385–6388.
26.
ClermontO., LavollayM., VimontS., DeschampsC., ForestierC., BrangerC., DenamurE., and ArletG.. 2008. The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup. J. Antimicrob. Chemother., 61:1024–1028.
27.
Clinical and Laboratory Standards Institute (CLSI). 2015. M100-S25 Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement. CLSI, Wayne, PA.
28.
Clinical and Laboratory Standards Institute (CLSI). 2015. M7-A10 Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, Tenth ed. Approved Standard. CLSI, Wayne, PA.
29.
European Committee on Antimicrobial Susceptibioity Testing (EUCAST). EUCAST Clinical Brealpoint Tables v.7.1 varid from 2017–03-10. Available at www.eucast.org/clinical_breakpoints/.
30.
BenjaminiY., and HochbergY.. 1995. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Statist. Soc. B., 57:289–300.
31.
LuvsansharavU-O., HiraiI., NikiM., NakataA., YoshinagaA., YamamotoA., YamamotoM., ToyoshimaH., KawakamiF., MatsuuraN., and YamamotoY.. 2013. Fecal carriage of CTX-M β-lactamase-producing Enterobacteriaceae in nursing homes in the Kinki region of Japan. Infect. Drug. Res., 6:67–70.
32.
HogardtM., ProbaP., MischelerD., CunyC., KempfV.A., and HeudorfU.. 2015. Current prevalence of multidrug-resistant organisms in long-term care facilities in the Rhine-Main district, Germany, 2013. Euro. Surveill., 20: pii: 21171.
33.
WillemsenI., NelsonJ., HendricY., MuldersA., VerhoeffS., MulderP., RoosendaalR., van der ZwaluwK., VerhulstC., van der BerghM.K., and KluytmansJ.. 2015. Extensive dissemination of extended spectrum β-lactamase-producing Enterobacteriaceae in a Dutch nursing home. Infect. Control. Hosp. Epidemiol., 36:394–400.
34.
NyS., LöfmarkS., BörjessonS., EnglundS., RingmanM., BergströmJ., NaucérP., GiskeC.G., and ByforsS.. 2017. Communuty carriage of ESBL-producing Escherichia coli is associated with strains of low pathogenicity: a Swedish nationwide study. J. Antimicrob. Chemother., 72:582–588.
35.
MatsumuraY., JohnsonJ.R., YamamotoM., NagaoM., TanakaM., TakakuraS., and IchiyamaS.; on behalf of the Kyoto-Shiga Clinical Microbiology Study Group. 2014. CTX-M-27 and CTX-M-14-producing, ciprofloxacin-resistant Escherichia coli of the H30 subclonal group within ST131 drive a Japanese regional ESBL epidemic. J. Antimicrob. Chemother., 70:1639–1649.
36.
MatsumuraY., YamamotoM., HiguchiT., KomoriT., TsuboiF., HayashiA., SugimotoY., HottaG., MatsushimaA., NaganoM., TakakuraS., and IchiyamaS.. 2012. Prevalence of plasmid-mediated AmpC β-lactamase-producing Escherichia coli and spread of the ST131 clone among extended-spectrum β-lactamase-producing E. coli in Japan. Int. J. Antimicrob. Agents., 40:158–162.
37.
OverdevestI., HaverkateM., VeenemansJ., HendriksY., VerhulstC., MuldersA., CouprieW., BootsmaM., JohnsonJ., and KluytmansJ.. 2016. Prolonged colonization with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonization, the Netherlands, 2013 to 2014. Euro. Surveill., 21:1–10.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
